The 31-valent pneumococcal vaccine maintained immune responses across a broader range of serotypes while showing safety comparable to two approved vaccines.
Key Takeaways
- VAX-31 met all prespecified primary endpoints in the Phase 3 OPUS-1 trial.
- It contains all 20 serotypes in Pfizer’s Prevnar 20 plus 11 additional serotypes.
- The trial measured immune responses and safety—not reductions in pneumonia cases.
Data Snapshot
| Item | Details |
|---|---|
| Company | Vaxcyte |
| Candidate | VAX-31 |
| Modality | 31-valent pneumococcal conjugate vaccine |
| Trial | OPUS-1 Phase 3 |
| Participants | 4,047 U.S. adults |
| Comparators | Prevnar 20 and Capvaxive |
| Result | All prespecified primary endpoints met |
| Next steps | OPUS-2 and OPUS-3 in H1 2027; BLA planned for H1 2028 |
What Happened
Vaxcyte reported positive topline results from OPUS-1, a randomized, double-blind Phase 3 trial conducted at approximately 30 U.S. sites.
Among adults aged 50 or older, all 28 VAX-31 serotypes shared with Prevnar 20 and/or Capvaxive met the prespecified primary noninferiority criterion. Three serotypes unique to VAX-31 and the cross-reactive serotype 20B also met the superiority criterion. (Vaxcyte OPUS-1 results)
In separate comparator-specific analyses, VAX-31 met the stricter noninferiority threshold for all 20 serotypes shared with Prevnar 20 and 17 of 19 shared with Capvaxive. Serotypes 3 and 12F missed the stricter threshold but met the historically used noninferiority standard.
VAX-31 showed a safety profile similar to both approved comparators. Most solicited reactions were mild or moderate and resolved within 48 hours, with no vaccine-related serious adverse events or discontinuations reported.
Independent coverage highlighted the clean Prevnar 20 comparison while noting that serotypes 3 and 12F may receive closer attention during FDA review. (Fierce Biotech analysis)
How VAX-31 Expands Pneumococcal Coverage
Pneumococcal conjugate vaccines link capsular polysaccharides from selected serotypes to carrier proteins. This recruits CD4-positive T-cell help, supporting B-cell activation, immune memory and production of serotype-specific opsonizing antibodies.
VAX-31 uses the same broad immune principle as Prevnar 20 but extends its serotype range:
- Prevnar 20: 20 serotypes
- VAX-31: the same 20 plus 11 additional serotypes
- VAX-31 total: 31 serotypes
Of the 11 additional serotypes, eight are also included in Capvaxive and three are absent from both approved comparators. Cross-reactive serotype 20B is evaluated separately and is not counted among the 31 vaccine serotypes.
Vaxcyte’s site-specific, carrier-sparing platform is designed to expand coverage without substantially weakening immune responses to individual serotypes. Earlier Phase 1/2 results supported the safety and immunogenicity of this approach. (VAX-31 Phase 1/2 study)
The image below compares the shared conjugate-vaccine mechanism and the difference in serotype coverage.
Competitive Landscape
| Company | Product | Serotypes | Status | Positioning |
|---|---|---|---|---|
| Pfizer | Prevnar 20 | 20 | FDA approved | Established franchise with commercial scale |
| Merck | Capvaxive | 21 | FDA approved for adults | Focused on serotypes causing adult disease |
| Vaxcyte | VAX-31 | 31 | Phase 3 | Broader coverage; approval remains pending |
| Pfizer | Adult 35-valent PCV | 35 | Preclinical; clinical entry planned | Potential next-generation competitor |
Pfizer’s 35-valent adult candidate is expected to enter clinical development by the end of 2026, meaning VAX-31’s coverage advantage may not remain uncontested. (Pfizer next-generation PCV program)
Why It Matters
Vaxcyte estimates that VAX-31 could cover approximately 95% of invasive pneumococcal disease and 88% of pneumococcal pneumonia caused by circulating serotypes in U.S. adults aged 50 or older.
These are epidemiological coverage estimates, not observed clinical efficacy rates. OPUS-1 did not establish that VAX-31 prevents more pneumonia cases than Prevnar 20 or Capvaxive.
The remaining requirements include OPUS-2 and OPUS-3 results, manufacturing consistency data, FDA approval and a favorable U.S. vaccination recommendation.
BP View
OPUS-1 establishes VAX-31 as a credible scientific competitor to Pfizer and Merck. The key achievement was maintaining immune responses while expanding coverage to 31 serotypes.
Commercial success is less certain. Vaxcyte must compete with larger companies that already have manufacturing capacity, distribution networks, payer access and established vaccine franchises.
VAX-31 should therefore be viewed as a successful pivotal program with a compelling coverage profile—not yet as a proven replacement for approved pneumococcal vaccines.
If you have questions or a different view on VAX-31’s competitive potential, leave a comment below.
Related Post
For another Phase 3 story showing how vaccine technology is expanding beyond traditional infectious-disease prevention, read my previous analysis:
Moderna’s Personalized mRNA Cancer Therapy Delivers First Phase 3 Win
About BP
Biopharma Perspective provides concise, evidence-based analysis of clinical trials, regulatory decisions, drug mechanisms and competitive strategy across the global biopharmaceutical industry.
Leave a Reply